Get the latest tech news

From molecule to medicine, with Ross Rheingans-Yoo

What happens between academic research and patients getting access to new drugs, and how we can improve it.

[ Patrick notes: This makes Ross by my count the third former Jane Street employee we’ve had on Complex Systems, which is partially a reflection of my skewed personal and professional networks, and partly downstream of very interesting things they do with regards to identifying and attracting early-career talent.] Secondly, in the final resolution of the settlements, the estate agreed that while the potential returns from some equity investments I had directed would be recovered for the benefit of creditors, they would not seek to pull money out of the companies that were continuing to actively develop drugs and push those programs forward. Patrick McKenzie: One of the reasons this process feels interminably long to patients, who often wonder why their disease hasn't been cured yet, is that it takes many shots on goal to start entering the funnel before one eventually makes it through.

Get the Android app